Related references
Note: Only part of the references are listed.Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial
Boni E. Elewski et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial
Alice Gottlieb et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
Diamant Thaci et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study
D. Thaci et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2015)
Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE)
C. Paul et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2015)
Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis
A. Langenbruch et al.
BRITISH JOURNAL OF DERMATOLOGY (2014)
Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes
M. Augustin et al.
BRITISH JOURNAL OF DERMATOLOGY (2014)
Disease characteristics in patients with and without psoriatic arthritis treated with etanercept
K. Papp et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2014)
Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials
Richard G. Langley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Cytokine-Based Therapy in Psoriasis
Anupam Mitra et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2013)
Growth rate of human fingernails and toenails in healthy American young adults
S. Yaemsiri et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2010)
Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis
Wolfgang Hueber et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
The pathogenesis of psoriatic arthritis and associated nail disease: not autoimmune after all?
Dennis McGonagle et al.
CURRENT OPINION IN RHEUMATOLOGY (2009)
Approach to managing patients with nail psoriasis
K. Reich
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2009)
Interleukin-17 as a drug target in human disease
Stefan Ivanov et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2009)
Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year
Phoebe Rich et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Psoriasis of the nail: Anatomy, pathology, clinical presentation, and a review of the literature on therapy
Michael M. Jiaravuthisan et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2007)
National Psoriasis Foundation clinical consensus on disease severity
David M. Pariser et al.
ARCHIVES OF DERMATOLOGY (2007)
Classification criteria for psoriatic arthritis - Development of new criteria from a large international study
William Taylor et al.
ARTHRITIS AND RHEUMATISM (2006)
Modification of the nail psoriasis severity index
CA Parrish et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2005)
Nail Psoriasis Severity Index: A useful tool for evaluation of nail psoriasis
P Rich et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2003)
Share Paper
